<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628506</url>
  </required_header>
  <id_info>
    <org_study_id>IODOLIP Study</org_study_id>
    <nct_id>NCT05628506</nct_id>
  </id_info>
  <brief_title>Measurement of Iodolipids in the Thyroid Gland and Other Biological Samples</brief_title>
  <acronym>IODOLIP</acronym>
  <official_title>Measurement of Iodolipids in the Thyroid Gland and Other Biological Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Gerasimos Sykiotis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research project is an open, parallel-group, single centre, randomized controlled trial&#xD;
      that aims to assess the feasibility of measuring iodolipids in thyroid samples of patients&#xD;
      during routine thyroid surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty subjects will be included. Patients are randomized 1:1 to receive either a single oral&#xD;
      administration of a pharmacological dose of potassium iodide 20±4 hours before surgery (10&#xD;
      patients), or nothing (10 patients):&#xD;
&#xD;
        -  The dose administered will be 97.5 mg,&#xD;
&#xD;
        -  Patients allocated to the control group will not receive any drug.&#xD;
&#xD;
      Two thyroid samples will be taken from the surgical specimen by a pathologist. Each sample&#xD;
      will have a weight of approximatively 1 g, corresponding to a volume of approximately 1 cm3.&#xD;
      We will select material containing tissue that corresponds to normal thyroid parenchyma&#xD;
      (according to the preoperative ultrasound and direct inspection by the pathologist&#xD;
      intraoperatively). The sample will be taken in the dedicated room next to the operating room&#xD;
      by a pathologist who will confirm that the targeted area has no visible macroscopic lesion.&#xD;
      In case of doubt, an alternative area free of lesion will be selected by the pathologist.&#xD;
&#xD;
      Patients are unblinded. The total maximum duration of the study for an individual patient is&#xD;
      42 days. The total duration of the clinical trial will be 3 years in order to include 20&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">February 11, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean 2-iodoxehadecanal and delta-iodolactone in the thyroid sample</measure>
    <time_frame>20±4 hours after administration of potassium iodide</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Thyroid</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium iodide</intervention_name>
    <description>Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients fulfilling all of the following inclusion criteria are eligible for the study:&#xD;
&#xD;
          1. Patients with the capacity for discernment and who agree to participate in the study&#xD;
             and sign the consent.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. Indication for thyroid surgery due to either nontoxic single thyroid nodule (WHO&#xD;
             disease classification 5A01.1) or nontoxic multinodular goitre (WHO disease&#xD;
             classification 5A01.2).&#xD;
&#xD;
          4. Normal thyroid function without anti-thyroid medication. This is ascertained by at&#xD;
             least one serum TSH value within the reference range in the three months before&#xD;
             surgery (if multiple values are available, the latest value should be normal). If no&#xD;
             TSH values are available, a blood draw will be performed to measure TSH.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any one of the following exclusion criteria will lead to exclusion of the&#xD;
        patient:&#xD;
&#xD;
          1. Women who are pregnant or breastfeeding (a urine pregnancy test will be done at Visit&#xD;
             2 before randomization if applicable).&#xD;
&#xD;
          2. Intention to become pregnant during the course of the study.&#xD;
&#xD;
          3. Alcohol or drug abuse within the past 6 months.&#xD;
&#xD;
          4. Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the patient.&#xD;
&#xD;
          5. Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study.&#xD;
&#xD;
          6. Use, within the last month before the scheduled surgery, of iodine-containing&#xD;
             medications, i.e., iodine-containing anti-cough syrups or iodine-containing&#xD;
             disinfectants. Non-iodine-containing anti-cough syrups and non-iodine-containing&#xD;
             disinfectants are authorized.&#xD;
&#xD;
          7. Use, within the last month before the scheduled surgery, of iodine-containing&#xD;
             radiological contrast media. Non-iodine-containing radiological contrast media are&#xD;
             authorized.&#xD;
&#xD;
          8. Susceptibility to iodine-induced hyperthyroidism (i.e., toxic adenoma or toxic&#xD;
             multinodular goiter, or previous episode of iodine-induced hyperthyroidism according&#xD;
             to the medical history).&#xD;
&#xD;
          9. Serum TSH (thyroid-stimulating hormone) level below the lower limit of the reference&#xD;
             range.&#xD;
&#xD;
         10. Graves' disease.&#xD;
&#xD;
         11. Susceptibility to iodine-induced hypothyroidism (history of thyroid surgery,&#xD;
             Hashimoto's thyroiditis, history of subacute or destructive thyroiditis).&#xD;
&#xD;
         12. Titer of serum thyroid autoantibodies (anti-TSH receptor, anti-thyroperoxydase or&#xD;
             antithyroglobulin) above the reference range.&#xD;
&#xD;
         13. History of sialadenitis, regardless of etiology.&#xD;
&#xD;
         14. History of allergic reactions (any grade) to radiological contrast media,&#xD;
             iodine-containing disinfectants, anti-cough medications, or seafood; and known&#xD;
             hypersensitivity to iodine.&#xD;
&#xD;
         15. History of allergic reactions (any grade) to the excipients of the &quot;&quot;IODURE DE&#xD;
             POTASSIUM 65 AApot cpr 65 mg&quot; drug: lactosum anhydricum, cellulosum microcristallinum,&#xD;
             magnesii stearas.&#xD;
&#xD;
         16. Severe intolerance to lactose or galactose (patients having been recommended by their&#xD;
             physician to adhere to a strict regime free of the offending agent).&#xD;
&#xD;
         17. Concurrent treatment with lithium.&#xD;
&#xD;
         18. Concurrent treatment with potassium-sparing diuretics.&#xD;
&#xD;
         19. Nodule diagnosed as thyroid carcinoma or suspicious for thyroid carcinoma based on the&#xD;
             results of a fine-needle aspiration biopsy or a tru-cut biopsy (if performed during&#xD;
             the routine patient work-up as per standard indications).&#xD;
&#xD;
         20. Patients with hyperkalemia.&#xD;
&#xD;
         21. Dermatitis herpetiformis.&#xD;
&#xD;
         22. Congenital myotonia.&#xD;
&#xD;
         23. Hypocomplementemic urticaria/vasculitis.&#xD;
&#xD;
         24. Chronic obstructive pulmonary disease&#xD;
&#xD;
         25. Asthma&#xD;
&#xD;
         26. Heart failure stage B, C or D&#xD;
&#xD;
         27. Impaired renal function (eGFR &lt;60 ml/min/1.73 m2)&#xD;
&#xD;
         28. Normal urinary iodine concentration on the day of surgery (determined&#xD;
             retrospectively).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof. Gerasimos Sykiotis, MD, PhD</last_name>
    <phone>+41 (0)79 556 14 94</phone>
    <email>Gerasimos.Sykiotis@chuv.ch</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 24, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>November 24, 2022</last_update_submitted>
  <last_update_submitted_qc>November 24, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Prof. Gerasimos Sykiotis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

